Senator Calls for Mifepristone Oversight | US News

Senator Bill Cassidy’s new report accuses mifepristone manufacturers of failing to monitor how their abortion drug is prescribed and distributed—especially online—posing risks to patients and enabling coercion. He blames a 2016 FDA rule change for dropping complication reports and calls on regulators to enforce stricter oversight, while medical groups and the FDA defend the drug’s safety. A legal battle over mail-order access continues, with the Supreme Court blocking a court order to reinstate in-person requirements. The debate centers on who should control distribution: manufacturers, regulators, or doctors—and whether current safety data supports tighter controls. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0e1cb44b59c62a3f